Navigation Links
MU researchers studying model to learn why certain cancers become resistant to drugs

COLUMBIA, Mo. Resistance to chemotherapy treatments can be the worst news a cancer patient ever receives. A pair of researchers at the University of Missouri-Columbia is working steadfastly to learn why some tumors eventually build a tolerance to the common chemotherapy drug cisplatin, in hopes of identifying the particular genes that can be manipulated to make treatment as effective as possible.

In a paper published in the latest edition of Proceedings of the National Academy of Sciences (PNAS), Hannah and Stephen Alexander, professors of biological sciences in MUs College of Arts and Science, in collaboration with Gad Shaulsky and Adam Kuspa, professors at the Baylor School of Medicine, demonstrate that a model organism called Dictyostelium discoideum is useful for studying mechanisms of cisplatin drug sensitivity. Dictyostelium discoideum cells share many genes and biochemistry with human cells there are more than 30,000 genes in one human cell compared with 15,000 in Dictyostelium discoideum which simplifies the process of isolating and studying particular genes. The current study identified 400 genes that have the potential for use in improving cisplatin therapy.

The basic issue is that many types of cancer are treated with cisplatin, Stephen Alexander said. In some cases its the best drug, and in some cases its the only drug. Nevertheless, lots of cancers are either resistant to it or become resistant during treatment. Theres a lot of work being done in developing new drugs as cancer therapies, but not many of them have come on the market yet. Since cisplatin is effective and has already been approved, why not try to make it better"

During more than eight years of research, the Alexanders have examined why tumors become resistant to cisplatin and what, if any, biochemical pathways can be used to improve the drugs efficiency. They identified genes for sphingolipid metabolism as key to whether a tumor cell lives or dies after treatment with cisplatin. The current collaboration with the Baylor team has greatly expanded these studies.

Shaulsky and Kuspa have developed microarray technologies to determine the patterns of gene expression in Dictyostelium discoideum and detect the effects of treatments. Together, the teams of researchers embarked to find the global response to cisplatin and how mutants in sphingolipid metabolism resistant to cisplatin affected the response. The study established that the cause of resistance is not simply that cells do not take up the drug or that the drug is neutralized, but that a specific set of genes responds uniquely to the treatment. Finding ways to use those genes to increase sensitivity to cisplatin could lead to more effective therapy.

We used genetics to find genes that are involved, and we discovered several completely novel pathways that no one had ever thought was involved with this, Stephen Alexander said. Ultimately, were looking for a way to make cisplatin more effective, and the idea is to find out whats going on in the cell that determines whether cells are sensitive or not, and to boost some pathway to make it better.


Contact: Kevin Carlson
University of Missouri-Columbia

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers identify the early makers of Neonatal Sepsis
4. OHSU Researchers Announce New Discovery
5. Researchers Identify Gene Connected To Bipolar Disorder
6. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
7. Researchers trick Alzheimers Enzyme
8. Researchers find new HIV hiding place
9. Gene researchers make Malaria-resistant mosquito
10. New Hair in 15 Days Could Now Be A Possibility Say Researchers
11. Researchers developed world’s smallest toothbrus
Post Your Comments:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: